In addition, we asked if the group of JMML patients without clinical evidence of NF-1 and no mutation in PTPN11, KRAS, NRAS, or CBL (quintuple-negative, QN) contained unrecognized cases driven by NF1. Here, KRAS is linked to juvenile myelomonocytic leukemia.